NasdaqGM:LGNDPharmaceuticals
Why Ligand (LGND) Is Up 5.7% After Highlighting Royalty-Heavy 2026 Revenue Guidance
Earlier in December 2025, Ligand Pharmaceuticals issued 2026 guidance calling for total revenue of US$245 million to US$285 million, including US$200 million to US$225 million in royalty revenue, US$35 million to US$40 million in Captisol sales, and US$10 million to US$20 million in contract revenue.
This detailed breakdown highlights how reliant the company expects to be on high-margin royalty income, with smaller contributions from Captisol and contract work.
Next, we’ll examine how this...